April 20, 2018
Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions
NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of patient genotype-relevant preclinical models for assessing novel agents. A new publication details the preclinical evaluation of osimertinib for this EGFR mutation type, using a series of CRISPR-Cas9 engineered cell lines and patient-derived xenograft (PDX) models ...
LEARN MORE
April 13, 2018
The Establishment and Characterization of PDX Models
Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo oncology studies than ...
LEARN MORE
April 5, 2018
The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays
Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often used to reduce system ...
LEARN MORE
March 19, 2018
Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology
Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to cancer, with antibodies ...
LEARN MORE
March 13, 2018
ICOS: Immunostimulatory or Immunosuppressive Target?
The rise of immunotherapy has brought many new targets to the forefront of oncology drug development. One promising new ...
LEARN MORE
March 1, 2018
Using T Cells in Immuno-Oncology
Immuno-oncology drug development challenges researchers to model the interaction between novel immunotherapy agents, ...
LEARN MORE
February 27, 2018
CAR-T Cell Therapy: Use Earlier for Better Results
CAR-T cell therapies are still in their infancy as clinical oncology treatments, with the first agent approved just 6 months ago. It’s known that CD19 specific CAR-T therapies induce high rates of initial response in patients, but as the treatment modality is so new, long term response studies are lacking.
LEARN MORE
February 22, 2018
Tumor Infiltrating Lymphocytes: Conflicting Approaches in Immuno-Oncology
Today’s new frontier in cancer treatment is in fact a very, very old frontier indeed: tumor infiltrating lymphocytes ...
LEARN MORE
February 20, 2018
How to Assess CAR-T Cell Therapies Preclinically
Chimeric antigen receptor (CAR)-T cell therapies are a new and novel immuno-oncology treatment modality, only recently ...
LEARN MORE
February 16, 2018
3 Key Uses for Humanized Mouse Models
We’ve been focusing on humanized mouse models recently on our blog, from evolution of immunodeficient host mice through ...
LEARN MORE
January 30, 2018
Humanized Mouse Model Head to Head: hPBMC vs hCD34+
The future of cancer treatment is often considered to be combination regimens (dual immunotherapeutics or immuno-oncology + targeted agents), which is driving the need to develop models for the assessment of human-specific agents and combinations prior to clinical trial.
LEARN MORE
January 26, 2018
Comparison Guide: huNOG® & huNSG™ Humanized Models
Previously our blog posts have reviewed humanized mice, looking at hPBMC vs hCD34+ models, how they differ, and how to ...
LEARN MORE
January 5, 2018
2018 Technology Advances – Applying Next Generation Sequencing to Single Cell Analysis
It is an axiom in biology that expression of genotype determines phenotype. This means, for the large part, that the ...
LEARN MORE
December 19, 2017
2017 Review: Precision Medicine - From Traditional to Tailored Treatment
With continued advances in technology, and the increasing focus on individualized therapy, the field of precision ...
LEARN MORE
December 7, 2017
2017 Review: PARP Inhibitor Update and Approvals
As the holiday season approaches, CrownBio is celebrating with a look back over the important research and scientific ...
LEARN MORE
